Objectives: In this study we retrospectively reviewed A. baumannii meningitis cases treated with tigecycline including regimens and evaluated the efficacy of tigecycline in the therapy.
Patients And Methods: Study was performed in seven tertiary-care educational hospitals from five cities of Turkey and one center from France. We extracted data and outcomes of all adult (aged >18) patients with culture proven A. baumannii meningitis treated with tigecycline including antibiotic therapy until April 2016.
Results: A total of 23 patients (15 male and eight female) fulfilled our inclusion criteria. All Acinetobacter strains were carbapenem-resistant and susceptible to tigecycline. Six cases received tigecycline monotherapy while 17 received tigecycline including combination therapy (10 with colistin, 4 with netilmicin, 3 with amikacin, 4 with meropenem). Seven of 23 cases (30%) died during the tigecycline including therapy (1 in monotherapy, 4 in colistin, 2 in netilmicin, 1 amikacin, one case received tigecycline + netilmicin followed by tigecycline + colistin). Hence, overall end of treatment (EOT) success was 70%. However, since further 27% died due to additional nosocomial infections, overall clinical success (relieved symptoms at the EOT and one-month post-therapy survival without any relapse or reinfection) decreased to 43%.
Conclusion: We conclude that tigecycline may be an alternative in the salvage treatment of nosocomial multidrug-resistant Acinetobacter spp. meningitis. Acinetobacter spp. Meningitis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clineuro.2018.06.008 | DOI Listing |
J Fungi (Basel)
November 2024
Department of General ICU, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Pythiosis, a rare and formidable infectious disease caused by , is characterized by profound uncertainties in achieving definitive diagnoses, suboptimal outcomes, and an exceptionally high mortality rate. Here, we present a rare case of human spinal pythiosis in southern China. With advanced metagenomic sequencing technology, was pinpointed as the causative pathogen.
View Article and Find Full Text PDFMicrobiol Spectr
December 2024
Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China.
Unlabelled: Carbapenem-resistant spp. pose a significant challenge in clinical settings due to limited treatment options for nosocomial infections. Carbapenem-hydrolyzing class D beta-lactamases are the primary cause for carbapenem resistance, while metallo-beta-lactamases (MBLs) New Delhi metallo beta-lactamase (NDM) and imipenemase (IMP) also contribute.
View Article and Find Full Text PDFInt J Biol Macromol
December 2024
Grade 2022, Clinical Medicine, School of Basic Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, PR China.
The interaction mechanism of tigecycline with γ-globulin and hemoglobin in the absence and presence of amikacin was investigated through multipectral, molecular docking and molecular dynamics simulation. The results show that tigecycline and γ-globulin/hemoglobin forms a ground state complex without or with amikacin. The presence of amikacin slightly increases the binding constant of tigecycline to γ-globulin/hemoglobin, but all are of moderate binding affinity, at 10 L mol.
View Article and Find Full Text PDFSci Total Environ
December 2024
Institute of Food Safety and Nutrition, Jinan University, Guangzhou 510632, China. Electronic address:
Polymyxin B is one of the last lines of defense in infections caused by multidrug-resistant Gram-negative bacteria. Aeromonas hydrophila are important fish pathogens and the occurrence of polymyxin B-resistant A. hydrophila isolates is increasing.
View Article and Find Full Text PDFPoult Sci
December 2024
Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, Jiangsu Province, PR China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!